OverviewSuggest Edit

Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.

Regulus is also advancing several programs toward clinical development in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners.

TypePublic
Founded2007
HQSan Diego, CA, US
Websiteregulusrx.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2018)24(-61%)
Job Openings1
Revenue (FY, 2020)$10 M(+47%)
Share Price (Sept 2021)$0.7(-3%)
Cybersecurity ratingCMore

Key People/Management at Regulus Therapeutics

Cris Calsada

Cris Calsada

Chief Financial Officer
Stelios Papadopoulos

Stelios Papadopoulos

Director
Christopher Aker

Christopher Aker

Senior Vice President and General Counsel
David Baltimore

David Baltimore

Director
Jake R. Nunn

Jake R. Nunn

Director
Denis Drygin

Denis Drygin

Chief Scientific Officer
Show more

Regulus Therapeutics Office Locations

Regulus Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
4224 Campus Point Ct Suite 210
Show all (1)

Regulus Therapeutics Financials and Metrics

Regulus Therapeutics Revenue

Regulus Therapeutics's revenue was reported to be $10.01 m in FY, 2020
USD

Revenue (FY, 2020)

10.0m

Net income (FY, 2020)

(15.7m)

EBIT (FY, 2020)

(14.2m)

Market capitalization (14-Sept-2021)

54.6m

Closing stock price (14-Sept-2021)

0.7

Cash (31-Dec-2020)

31.1m

EV

28.1m
Regulus Therapeutics's current market capitalization is $54.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

20.8m1.2m72.0k72.0k6.8m10.0m

Revenue growth, %

171%(94%)(94%)

General and administrative expense

19.1m18.4m17.0m12.9m11.3m8.8m

R&D expense

56.4m64.3m53.2m34.0m12.3m15.3m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

489.0k483.0k204.0k18.0k18.0k18.0k18.0k36.0k18.0k6.8m18.0k18.0k6.0k5.0m

General and administrative expense

5.1m3.7m4.8m4.0m7.1m2.7m3.8m7.1m3.0m3.5m2.9m2.6m2.4m2.3m2.1m

R&D expense

16.8m18.0m14.6m15.8m14.3m12.7m11.8m21.8m6.9m6.0m1.8m2.4m3.1m4.2m4.0m

Operating expense total

21.9m21.7m19.4m19.7m21.3m15.4m15.6m29.0m9.9m9.5m4.7m5.0m5.5m6.5m6.1m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

16.0m14.9m13.5m13.9m34.1m31.1m

Accounts Receivable

1.1m503.0k

Prepaid Expenses

1.2m1.8m

Current Assets

134.3m87.5m66.7m19.3m40.4m36.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

19.2m27.0m14.7m14.9m12.5m20.2m10.1m13.5m14.1m10.3m19.6m14.6m28.1m23.4m17.8m

Accounts Receivable

286.0k13.0k2.8m331.0k699.0k676.0k674.0k4.0m

Prepaid Expenses

10.6m4.2m3.8m3.8m3.8m3.9m3.9m3.4m

Current Assets

115.8m116.2m102.8m67.6m49.9m79.6m51.4m39.2m25.4m17.7m24.3m19.5m33.6m28.6m26.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(55.7m)(81.8m)(71.9m)(48.7m)(18.6m)(15.7m)

Depreciation and Amortization

1.6m2.3m2.5m2.3m

Accounts Payable

529.0k3.1m(65.0k)(4.0m)(393.0k)(786.0k)

Cash From Operating Activities

(49.9m)(56.9m)(58.8m)(43.3m)(19.8m)(12.5m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(21.2m)(21.1m)(19.5m)(20.0m)(57.5m)(16.0m)(29.9m)(40.1m)(3.3m)(8.3m)(13.7m)(5.9m)(12.9m)(14.4m)

Depreciation and Amortization

1.9m563.0k1.1m1.7m502.0k673.0k800.0k126.0k248.0k362.0k

Accounts Payable

3.6m3.5m5.7m4.5m4.9m(579.0k)(1.3m)(276.0k)(4.5m)936.0k(112.0k)(193.0k)(291.0k)(297.0k)(219.0k)

Cash From Operating Activities

(47.7m)(15.6m)(27.8m)(39.3m)(4.4m)(10.1m)(14.8m)(6.0m)(11.2m)(15.7m)
USDFY, 2015

Revenue/Employee

235.9k

Financial Leverage

1.1 x
Show all financial metrics

Regulus Therapeutics Operating Metrics

FY, 2016

Patents Issued

300
Show all operating metrics

Regulus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Regulus Therapeutics Online and Social Media Presence

Embed Graph

Regulus Therapeutics News and Updates

Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals?

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter...

Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

LA JOLLA, Calif., Dec. 16, 2019 / / -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted the Partial Clinical Hold on the…

Regulus Therapeutics Announces RGLS4326 Program Update

LA JOLLA, Calif., July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326 for the treatment of Autosomal Dominant ...

Regulus Therapeutics Blogs

Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO , Sept. 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan , President and Chief Executive Officer

Senior Research Associate/Senior Scientist, Chemistry

Position description and scope: The successful candidate will be a member of the chemistry Team. The candidate chemist will be responsible for the design, synthesis, purification, and analysis processes required to produce a wide range of modified and/or conjugated oligonucleotides. Primary responsi…

Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates

Completed Preparations and Request for FDA Meeting to Obtain Feedback on Approach to Addressing Remaining Hold Requirements Completed Enrollment in Second Cohort of Trial; Topline Data Expected in the Fourth Quarter Extended Expected Cash Runway into Q4 2022 with $15.4 Million Raised through its

Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call

Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call Content Import Tue, 08/03/2021 - 17:15 Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call Aug 03, 2021 …

Vice President, Chemistry and Pharmaceutical Development

Position description and scope: The successful candidate will lead the Chemistry and Pharmaceutical Development teams and will provide preclinical research and GMP development direction of effective strategies implementation to support research and preclinical program activities, clinical trials, re…

Senior Research Associate – Scientist

Position description and scope: This position is intended for a highly qualified candidate who desires the opportunity to grow as a drug discovery scientist and project team leader in the fields of microRNA and CNS-related therapeutics.  The successful candidate will be a hands-on cell and molecular…
Show more

Regulus Therapeutics Frequently Asked Questions

  • When was Regulus Therapeutics founded?

    Regulus Therapeutics was founded in 2007.

  • Who are Regulus Therapeutics key executives?

    Regulus Therapeutics's key executives are Cris Calsada, Stelios Papadopoulos and Christopher Aker.

  • How many employees does Regulus Therapeutics have?

    Regulus Therapeutics has 24 employees.

  • What is Regulus Therapeutics revenue?

    Latest Regulus Therapeutics annual revenue is $10 m.

  • What is Regulus Therapeutics revenue per employee?

    Latest Regulus Therapeutics revenue per employee is $416.9 k.

  • Who are Regulus Therapeutics competitors?

    Competitors of Regulus Therapeutics include Keros Therapeutics, Moderna and CureVac.

  • Where is Regulus Therapeutics headquarters?

    Regulus Therapeutics headquarters is located at 4224 Campus Point Ct Suite 210, San Diego.

  • Where are Regulus Therapeutics offices?

    Regulus Therapeutics has an office in San Diego.

  • How many offices does Regulus Therapeutics have?

    Regulus Therapeutics has 1 office.